Catamero D et al. A focus on CAR T-cell therapy and bispecific antibodies in multiple myeloma. J Adv Pract Oncol 2022;13(Suppl 4):31-43. Abstract

Chari A et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387(24):2232-44. Abstract

Mohty M et al. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study. ASCO 2023;Abstract 8039.

Munshi NC et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384(8):705-16. Abstract